BioGraphene Signs Collaboration Agreement with NICHD to Initiate Efficacy Studies of Graphene Quantum Dots in Lysosomal Storage Disorders Using Animal Models

BioGraphene Inc. announced that the company and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) entered into a Collaboration Agreement for BGN-112’s pharmacodynamic study.

Dr. Forbes Porter, a senior investigator & clinical director at NICHD will lead the research to assess the potential therapeutic efficacy of Graphene Quantum Dots (GQDs) to treat lysosomal storage diseases (i.e. Niemann-Pick Disease Type C (NPC)) in various model systems.

Dr. Porter’s research group investigates molecular, biochemical, cellular, and developmental processes that underlie genetic syndromes. Specifically, his research has focused on rare genetic disorders like NPC. NPC is a neurodegenerative, lysosomal disease due to impaired intracellular cholesterol transport. His research group combines both basic science and clinical expertise to develop and test novel therapeutic interventions for rare genetic disorders.